JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Rachel Vatnsdal maintains a Neutral rating on 10x Genomics (NASDAQ:TXG) and lowers the price target from $20 to $14.
October 30, 2024 | 4:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan has maintained a Neutral rating on 10x Genomics and reduced the price target from $20 to $14, indicating a less optimistic outlook.
The reduction in price target from $20 to $14 by JP Morgan suggests a less favorable view on 10x Genomics' future performance, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100